Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5633-5640

  Solban, Nicolas ^a   Pal, Selbo K ^b   Alok, Sinha K ^a   Sung, Chang K ^a   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOTOSENSITIZING AGENT; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LEVEL; CELL STRAIN LNCAP; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; TRANSCRIPTION INITIATION;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSTATIC NEOPLASMS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745241387     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0604     Document Type: Article

References (50)

1. Kasan T, Ortel B, Solban N, Pogue B. Photodynamic therapy of cancer. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock R, Weichselbaum RR, Gansler T, Holland JF, Frei E III, editors. Cancer Medicine. 7th ed. Hamilton (Ontario, Canada): BC Decker, Inc.; 2006. p. 537-48.
2. Solban N, Ortel B, Pogue B, Hasan T. Targeted optical imaging and photodynamic therapy. Ernst Schering Res Found Workshop 2005;49:229-58.
3. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508.
4. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002;20:3-7.
5. Windahl T, Andersson SO, Lofgren L. Photodynamic therapy of localised prostatic cancer. Lancet 1990;336:1139.
6. Nathan TR, Whitelaw DE, Chang SC, et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 2002;168:1427-32.
7. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 1998;77:1386-94.
8. Henderson BW, Busch TM, Vaughan LA, et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 2000;60:525-9.
9. Chen Q, Huang Z, Chen H, Shapiro H, Beckers J, Hetzel FW. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol 2002;76:197-203.
10. Engbrecht BW, Menon C, Kachur AV, Hahn SM, Fraker DL. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res 1999;59:4334-42.
11. Fingar VH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer 1999;79:1702-8.
12. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001;13:167-71.
13. Michel G, Minet E, Mottet D, Remade J, Michiels C. Site-directed mutagenesis studies of the hypoxia-inducible factor-1α DNA-binding domain. Biochim Biophys Acta 2002;1578:73-83.
14. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
15. Deininger MH, Weinschenk T, Morgalla MH, Meyermann R, Schluesener HJ. Release of regulators of angiogenesis following hypocrellin-A and -B photodynamic therapy of human brain tumor cells. Biochem Biophys Res Commun 2002;298:520-30.
16. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000;60:4066-9.
17. Jiang F, Zhang ZG, Katakowski M, et al. Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem Photobiol 2004;79:494-8.
18. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.
19. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002;62:3956-61.
20. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-7.
21. Chen B, Pogue BW, Zhou X et al. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005;11:720-7.
22. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998-99;17:279-84.
23. Ferrario A, Fisher AM, Rucker N, Gomer CJ. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005;65:9473-8.
24. Merlin JL, Azzi S, Lignon D, Ramacci C, Zeghari N, Guillemin F. MTT assays allow quick and reliable measurement of the response of human tumour cells to photodynamic therapy. Eur J Cancer 1992;28A:1452-8.
25. Uthoff SM, Duchrow M, Schmidt MH, et al. VEGF isoforms and mutations in human colorectal cancer. Int J Cancer 2002;101:32-6.
26. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res 2005;65:564-73.
27. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 2004;14:123-30.
28. Pages G, Berra K, Milanini J, Levy AP, Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Them 2000;275:26484-91.
29. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRXA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 2002;291:908-14.
30. Fukumura D, Yuan F, Monsky WL, Chen Y, Jain KK. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 1997;151:679-88.
31. Monsky WL, Mouta Carreira C, Tsuzuki Y, Gohongi T, Fukumura O, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002;8:1008-13.
32. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J 2001;15:1312-4.
33. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-induciblc factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
34. Weersink RA, Bogaards A, Gertner M, et al. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photndynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B 2005;79:211-22.
35. Zhu TC, Finlay JC, Hahn SM. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B 2005;79:231-41.
36. Chen B, Pogue HW, Luna JM, Hardman RL, Hoopes PJ, Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res 2006;12:917-23.
37. Nowis O, Makowski M, Stoklosa T, Legat M, Issat T, Golab J. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 2005;52:339-52.
38. Specht KG, Rodgers MA. Plasma membrane depolarization and calcium influx during cell injury by photodynamic action. Biochim Biophys Acta 1991;1070:60-8.
39. Kunz L, Stark G. Photofrin II sensitized modifications of ion transport across the plasma membrane of an epithelial cell line. 1. Electrical measurements at the whole-cell level. J Membr Biol 1998;166:179-85.
40. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
41. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267:26031-7.
42. Cohen T, Gitay-Goren H, Sharon R, et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol them 1995;270:11322-6.
43. Tao J, Sanghera JS, Pelech SI, Wong G, Levy JG. Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative. J Biol Chcm 1996;271:27107-15.
44. Tong Z, Singh G, Valerie K, Rainbow AJ. Activation of the stress-activated JNK and p38 MAP kinases in human cells by photofrin-mediated photodynamic therapy. J Photochem Photobiol B 2003;71:77-85.
45. 1 integrin expression in ovarian cancer cells. Br J Cancer 1999;80:946-53.
46. Rousset N, Vonarx V, Eléouet S. et al. Effects of photodynamic therapy on adhesion molecules and metastasis. J Photochem Photobiol B Biol 1999;52:65-73.
47. Dougherty TJ, Marcus SL. Photodynamic therapy. Eur J Cancer 1992;28A:1734-42.
48. Luna MC, Ferrario A, Wong S, Fisher AM, Gomer CJ. Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. Cancer Res 2000;60:1637-44.
49. Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics 2005;5:173-90.
50. Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol 2005;56:569-77.